OVARIAN SEROUS ADENOCARCINOMA

This study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …

This study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which stops cancer cells from repairing themselves)—works better than olaparib alone for people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer…

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer. About 88 newly diagnosed patients will receive either the drug combo or chemo alone before and after surgery. Th…

This study tested two different ways of giving the chemotherapy drug paclitaxel (either once every three weeks or once a week) along with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goa…

This study tests a new way to treat ovarian cancer that has come back after standard chemotherapy. Doctors take stem cells from fat tissue, infect them with a specially modified measles virus, and inject them into the belly. The stem cells carry the virus directly to cancer cells…

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …

This study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…